Revolution Medicines Begins Treatment in Phase 3 Zoldonrasib Trial
The company said treatment has begun in a global Phase 3 trial evaluating investigational zoldonrasib with pembrolizumab and chemotherapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Revolution Medicines begins Phase 3 RASolute 309 trial
Revolution Medicines said it has begun treating patients in its Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic cancer.
RVMD Begins Phase 3 Trial
Revolution Medicines starts treating patients in a Phase 3 clinical trial evaluating Zoldonrasib for RAS G12D metastatic pancreatic cancer